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Abstract. Mixed-effects models provide a rich theoretical framework
for the analysis of longitudinal data. However, when used to analyze or
predict the progression of a neurodegenerative disease such as Alzheimer’s
disease, these models usually do not take into account the fact that
subjects may be at different stages of disease progression and the in-
terpretation of the model may depend on some implicit reference time.
In this paper, we propose a generative statistical model for longitudinal
data, described in a univariate Riemannian manifold setting, which esti-
mates an average disease progression model, subject-specific time shifts
and acceleration factors. The time shifts account for variability in age
at disease-onset time. The acceleration factors account for variability
in speed of disease progression. For a given individual, the estimated
time shift and acceleration factor define an affine reparametrization of
the average disease progression model. This statistical model has been
used to analyze neuropsychological assessments scores and cortical thick-
ness measurements from the Alzheimer’s Disease Neuroimaging Initiative
database. The numerical results showed that we can distinguish between
slow versus fast progressing and early versus late-onset individuals.
1 Introduction
The Alzheimer’s disease (AD), and most neurodegenerative diseases alike, is a
slowly progressive neurodegenerative disorder and a growing public health issue
as the number of people diagnosed with AD is steadily increasing over the years,
partly due to an increasing ageing population. The progressive loss of cognitive
functions, such as memory, language and reasoning, are the observable conse-
quences of pathological processes which started to affect the brain several years
before. In [1], Clifford R. Jack et al. proposed a widely accepted hypothetical
model which describes the temporal evolution of the AD biomarkers in which
the decline in cognitive functions and memory loss occur in the late stages of
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the disease. The impairment of the cognitive functions is preceded by decreasing
cerebrospinal fluid (CSF) amyloid-β42 (Aβ1−42) peptide, increasing CSF tau
protein and neurodegeneration, characterized by cerebral atrophy and neuron
loss. In order to increase the chances of success of a given treatment, the need
for an early diagnosis and the need to understand the progression of the disease
are crucial.
Longitudinal data, which consists in repeated observations of a given individ-
ual or group of individuals over time, allows to study the progression of a disease
and the statistical analysis of longitudinal data may provide useful informations
to help diagnose AD in its early phase. Mixed effects models provide a rich
framework to analyze longitudinal measurements. The fixed (and respectively
random) effects allow to describe the model at the group (respectively sub-
ject) level and the distribution of the random effects accounts for inter-subject
variability. A particular case of the linear mixed-effects models introduced by
Laird and Ware in [5] can be used to model a linear relationship between uni-
variate longitudinal measurement and the times of observation : the random
slope and intercept model. If yi,j denotes the j-th observation of the i-th sub-
ject associated to time ti,j , the random slope and intercept model would write
: yi,j = (a + ai)(ti,j − t0) + (b + bi) + εi,j , where εi,j denotes a Gaussian noise
with zero mean. The fixed effects a and b respectively correspond to the slope
and intercept of an average trajectory D(t) = a(t− t0) + b whereas t0 plays the
role of a reference time. The subject-specific slope ai and bi correspond to the
slope and intercept of the trajectory of the i-th individual.
If the longitudinal observations arise, for example, from developmental stud-
ies, breeding studies or pharmacological studies, there is a natural choice for the
baseline time t0, which may represent the time of birth, beginning of the study
or time at which a certain drug has been administered. In those situations, the
baseline time is known and is therefore not estimated along with the parame-
ters of the model. However, in studies on neurodegenerative diseases, such as
Alzheimer’s disease, there may be no natural choice for the reference time. As
pointed out by Yang et al. in [4] and Delor et al. in [3], the disease-onset time
is probably different for every individual and, at a given age, two individuals
may be at very different stages of disease progression. When the baseline (or
disease-onset) time is unknown, one may consider it as a fixed effect of the given
model. In [2], the authors proposed an interesting mixed-effect model for scalar
measurements but the model did not account for the difference in stages pro-
gression among individuals. Yang et al. [4] and Delor et al. [3] addressed this
issue by including time shifts in their models but Yang et al. did not estimate
the time shifts in a statistical framework. In Delor et al., the observations of
a given individual were shifted in time before the estimation of a disease-onset
time. In both situations, the reference time was not estimated. In [8], Singh et
al. proposed an interesting model for longitudinal manifold-valued observations
using parallel transport. However, if the model is written for univariate longitu-
dinal data, the model does include a random effect to account for the variability
in speed of disease progression.
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When the time reference time t0 is considered unknown, the linear model
given above is not identifiable and there is a relation between the distribution
of the intercept random effect bi and the fixed effect t0, which makes the inter-
pretation of the distribution of the intercept random effect bi difficult.
To address the issues we pointed out, we propose to replace the intercept
random effect bi, which characterizes the distribution of the measurement values
at time t0, by a time shift τi which measures the delay (or advance) in disease
progression. We therefore consider the model : yi,j = v0αi(ti,j − t0 − τi) + εi,j
where αi is a random effect log-normally distributed with mean equal to 1 and
τi is the time shift random effect normally distributed with mean 0. The fixed
effect v0 correspond to the slope of the mean trajectory and is the fixed effect
associated to αi whereas t0 is now the fixed effect associated to the random effect
τi. If D denotes the straight line D(t) = v0(t − t0), the model writes : yi,j =
D
(
αi(ti,j−t0−τi)+t0
)
+εi,j . As a consequence, the random effects αi and τi allow
to define a subject-specific affine reparametrization of the straight line D, which
can be thought of as an average trajectory. The acceleration factor αi and the
time shift τi of the affine subject-specific reparametrization provide informations
on the dynamical evolution of a given subject with respect to the average model:
the acceleration factor will determine whether an individual is progressing faster
than the individual trajectory. The time shift determines whether the individual
is lagging behind or ahead of the average model. Therefore, the random effects of
the model will allow to determine, among a group of individuals, who are fast or
slow progressing individuals and whether a given individual might develop the
disease earlier (early-onset) or later (late-onset) than the estimated reference
time t0.
Moreover, since the subject-specific trajectories are affine reparametrizations
of an average trajectory, this model can easily be generalized to longitudinal
measurements on a Riemannian manifold. The average trajectory may be re-
placed with a geodesic of the manifold and the subject-specific trajectories will
remain geodesics on the manifold. As a matter of fact, longitudinal measure-
ments arising from neuroimaging, neuropsychological tests or clinical examina-
tions may belong to nonlinear spaces. The scores to a neuropsychological test
often belong to a bounded interval. Riemannian manifolds offer a very flexible
framework which includes the previous examples. The generalization of this sta-
tistical model to Riemannian manifold-valued observations could be used either
to analyze shapes, cortical thickness measurements or neuropsychological assess-
ment scores. After a proper renormalization, the ADAS-Cog 13 scores belong to
the open unit inverval (0, 1) which, equipped with a specific metric, can be seen
as a univariate Riemannian manifold. For this metric, the geodesics are logistic
curves. The models presented in [2] and [3] do not generalize to manifold-valued
data. In [9], Lorenzi et al. used Riemannian manifold techniques to estimate a
model of the brain’s normal ageing from healthy individuals T1 MR scans. The
model was used to compute a time shift, called morphological age shift, which
corresponds to the actual anatomical age of the subject with respect to an esti-
mated average age for healthy subjects. However, the subject-specific time shifts
4 J.-B. Schiratti et al.
were not estimated as parameters of a statistical model. In [7], Datar et al. gen-
eralized a particular linear mixed-effects model to longitudinal shape analysis
but the proposed model did not include time shifts to account for the variability
in stages of disease progression among the population. Even though the model
is used to analyze shapes (given by a set of points), the model is not described
in a Riemannian manifold setting.
The work presented herein will generalize the model written above to a Rie-
mannian manifold included in IR. In Section 2, we will introduce our model and
we will present two particular cases of this model : the straight lines model and
the logistic curves model. We also explain how the parameters of the model are
estimated. In Section 3, the straight lines model and logistic curves model were
used to analyze longitudinal ADAS-Cog and cortical thickness measurements
from the ADNI database. We show that the estimated random effects of the
model allowed to distinguish between slow versus fast progressing individuals
and early versus late-onset individuals.
2 A mixed-effects model with time reparametrization for
manifold-valued observations
2.1 Model description
Let us assume that we observe p different individuals. For each individual, we
have ni observations, obtained at times ti,1 < . . . < ti,ni and the observations of
the i-th individual are denoted by yi,1, . . . , yi,ni . We assume that each observa-
tion yi,j is a point on a one-dimensional Riemannian manifold (M, g) included
in IR. In addition to this, we assume that the geodesics of M are defined on the
entire real line.
Let p0 be a point in M , t0 in IR and v0 ∈ Tp0M , a tangent vector to M
at the point p0. The triplet (p0, t0, v0) allows to define an average trajectory
γp0,t0,v0 , the geodesic of M which passes through the point p0 ∈ M at time t0
and with the velocity v0 ∈ Tp0M ' IR. This average trajectory summarises the
progression of all the individuals and could be interpreted as the evolution of
an “average subject”. While the average subject passes through the point p0 at
time t0 with the velocity v0, we assume that the trajectory of the i-th subject is
the geodesic γi which passes through the point p0 at time t0 + τi with velocity
αiv0. The parameters (p0, t0, v0) will be the fixed effects of the model whereas
αi and τi will be the random effects of the model. The point p0 in M can be
understood as an observation point. A simplistic interpretation of the role played
by αi and τi is the following : an observer standing at the point p0 in M and
aware that the average subject passes through the point at the time t0, with ve-
locity v0, will be able to tell whether the i-th subject passes through this point
earlier or later than the average subject and whether he passes faster or slower.
More precisely, τi is a time shift which will provide an information on whether
the progression of the i-th trajectory is ahead of the average trajectory or not
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and αi provides the information on whether the i-th subject is evolving faster
or slower than the average subject. As a consequence, the random effects αi and
τi take into account the fact that two different subjects may be at very different
stages of disease progression and allow for inter-subjects comparaisons. The de-
scription above makes the assumption that every subject-specific trajectory of
disease progression will eventually reach a common value p0. This assumption
does not make sense in a higher-dimensional Riemannian manifold. In order to
generalize the proposed model to a higher-dimensional setting, one would need
to add another random effect, associated to the fixed effect p0.
For a point p0 ∈M and t0 ∈ IR, v0 ∈ Tp0M , we define γp0,t0,v0 := Expt0,p0(αiv0)(·)
as the geodesic which passes through the point p0 at time t0 with velocity v0
: γp0,v0,t0 is the unique curve, drawn on M and defined on IR, which satisfies
∇γ˙p0,t0,v0 γ˙p0,t0,v0 = 0 and γp0,t0,v0(t0) = p0, γ˙p0,t0,v0(t0) = v0. For the dataset
(ti,j , yi,j) (1 ≤ i ≤ p and 1 ≤ j ≤ ni), we assume the following model :
yi,j = Expt0+τi,p0(αiv0)(ti,j) + εi,j (1)
where αi = exp(ηi) and : 
ηi ∼ ⊗pi=1 N (0, σ2η)
τi ∼ ⊗pi=1 N (0, σ2τ )
εi,j ∼ ⊗i,j N (0, σ2).
The random variables (ηi)1≤i≤p and (τi)1≤i≤p are assumed independent. The
vector θ = (p0, t0, v0, ση, στ , σ)
> is the vector of the parameters of the model.
We will discuss later how this vector is estimated from the data.
An important feature of the model (1) is that in can be written as follows :
yi,j = γp0,t0,v0
(
αiv0(ti,j − t0 − τi)
)
+ εi,j (2)
= γi(ti,j) + εi,j . (3)
The subject-specific trajectory of the i-th subject, the geodesic γi, therefore ap-
pears as an affine reparametrization of the average trajectory γp0,t0,v0 . As a con-
sequence, in order to compare the progession of a given individual with respect
to the average trajectory (respectively compare two given subjects together),
one only need to compare the affine reparametrization t 7→ αiv0(t − t0 − τi)
with the identity map t 7→ t (respectively, compare the slopes and intercepts
of the two subject-specific affine reparametrization). We can observe that these
reparametrization play the same role as the time warps which were introduced
by Durrleman et al. in [11] and [10], in the context of longitudinal shape analysis.
The time warps considered in those papers were diffeomorphisms of the real line
which accounted for the different rates of shape changes and were constructed
using the LDDMM framework : the diffeomorphism was obtained by integration
of a time-varying vector field which belongs to a Gaussian reproducing kernel
Hilbert space. The affine reparametrizations (with non-zero intercept) are also
diffeomorphisms but only model a constant rate of progression. However, with
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only two random effects, we are able to describe the progression of a given subject
in a realistic and easily interpretable manner.
Considering p0 as a fixed effect of the model and estimating p0 along with
the other fixed effects ensures that the estimated p0 will be the best observation
point possible. It should be noted that the model does not depend on a reference
time because if the observations (ti,j , yi,j) are transformed into (ti,j + t
′
0, yi,j)
then, only the estimated value of t0 will change whereas the variance parame-
ters will remain the same. Therefore, the interpretation of the random effects
(and between-subjects or subjects-average comparaisons) do not depend on the
timeline.
2.2 The straight lines model
In this section, we will illustrate the flexibility of the model we introduced in
the previous section. The choice of the Riemannian metric on M determines the
shape of the geodesics of M . By taking the canonical metric on IR, the geodesics
will be straight lines.
When M = IR is equipped with the canonical metric, M is a geodesically
complete Riemannian manifold and the geodesics of M are of the form t 7→
p+ tv. In this case, (1) writes :
yi,j = p0 + αiv0(ti,j − t0 − τi) + εi,j . (4)
Even though the model is called “linear”, (4) does not belong to the class of
linear mixed-effects models introduced in [5].
2.3 The logistic curves model
The situation when M = (0, 1) may arise when the observations are natu-
rally bounded. For example, neuropsychological assessments such as ADAS-Cog
or MMSE produce positive scores which are bounded above by a maximum
score. The 13 questions ADAS-Cog assessment test is marked out of 85 points.
Therefore, a typical ADAS-Cog score is a number in [0, 85]. By a proper renor-
malization, the score values can be considered as points in the interval (0, 1).
Fitting a linear model to such observations might not be such a good idea
since the fitted trajectories will not always remain in the domain (0, 1). On
the other hand, (0, 1) corresponds to the range of logistic curves with asymp-
tote equal to 1. In order to equip the open interval (0, 1) with a Riemannian
manifold structure, we must give a Riemannian metric. At a point p0 ∈ (0, 1),
the tangent space Tp0M is isomorphic to IR. For all p0 in M , we define gp0 to
be the following inner product : ∀(u, v) ∈ Tp0M, gp0(u, v) = uM(p0)v where
M(p0) =
1
p20(1−p0)2 . The mapping p0 7→ gp0 is smooth on M and defines
a Riemannian metric on M . In this particular setting, the geodesic equation
∇γ˙ γ˙ = 0 writes : γ¨(t) + Γ 11,1(γ(t))(γ˙(t))2 = 0 where Γ 11,1 is the Christoffel
symbol determined by the only coefficient g1,1(t) = M(t) of the metric. The
A mixed-effects model for longitudinal univariate manifold-valued data 7
geodesic equation writes : γ¨(t) − ( 1γ(t) + 1γ(t)−1)(γ˙(t))2 = 0, or equivalently :
γ(γ − 1)γ¨ − (2γ − 1)(γ˙)2 = 0. Solving for this differential equation allows to de-
termine that the geodesics of M are logistic curves of the form t 7→ 11+a exp(−rt)
with a > 0 and r ∈ IR. The geodesics are defined on IR and therefore ensure that
M is a geodesically complete Riemannian manifold. In this case, (1) writes :
yi,j =
1
1 +
(
1
p0
− 1) exp (− αiv0p0(1−p0) (ti,j − t0 − τi)) + εi,j . (5)
2.4 Estimation of the parameters of the model
The satistical model described in (1) is a nonlinear mixed-effects model with
gaussian random effects. Such models have been extensively studied in the lit-
terature and several methods exist for maximum likelihood estimation. The es-
timation of the parameters (p0, t0, v0, ση, στ , σ) was coded into the SAS software
(SAS Institute) using the Gauss-Hermite quadrature approximation with one
quadrature point. This quadrature approximation method is equivalent to the
Laplace approximation of the observed likelihood. During the estimation pro-
cedure, the objective function resulting from the Laplace approximation was
minimized using the Newton-Raphson algorithm or the Nelder-Mead simplex
algorithm. It should be mentioned that these estimation procedures were quite
sensitive to the choice of starting values. However we observed that this method
was more efficent and more robust than the Alternating Algorithm, proposed by
Lindstrom and Bates in [13] or Pinheiro and Bates in [12], and implemented in
other softwares.
3 Results
3.1 Data
We used data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI)
database [15]. The ADAS-Cog scores we used were collected for 1391 individu-
als enrolled in the ADNI1, ADNIGO and ADNI2 phases and cortical thickness
measurements for 725 individuals from the ADNI1 database. The longitudinal
follow-up of these individuals ranges from 18 months to 4 years. Diagnoses were
recorded for every individual and at each visit. These subject-specific sequences
of diagnoses allowed to classify the individuals into 4 groups of interest : sta-
ble controls (329 individuals), stable mild cognitive impairment, also denoted as
stable MCI (471 individuals), stable Alzheimer patients (248 individuals) and
converters MCI (282 subjects). Cortical thickness measurements were available
for 194 stable controls, 182 stable MCI, 170 converters MCI and 162 Alzheimer
patients. The individuals who reverted to control or MCI were not included in
these groups.
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3.2 Experimental results
The ADAS-Cog scores were normalized by 85, which corresponds to the maxi-
mum possible score, and analyzed using the logistic curves model. For each indi-
vidual, a couple of random variables (αi, τi) where αi = exp(ηi) were estimated
along with the parameters of the model. We recall that αi (and respectively τi)
account for the change in speed of disease progression (and respectively delay
in disease progression) of a given individual with respect to the average disease
progression trajectory. The couples (ηi, τi) have been plotted in figure 1.
Fig. 1. Log-acceleration factors ηi plotted against the time shifts τi for the 1391 individ-
uals with ADAS-Cog measurements. An horizontal line was plotted at the level ηi = 0
(no change in speed with respect to the average trajectory) and at τi = t0 = 77.17 (the
estimated reference time t0).
The results presented in figure 1 allow to compare the informations provided
by (ηi, τi) across the groups of interest we previously mentioned. We can ob-
serve that stable controls have larger time shifts than other groups. The stable
controls can be considered as late-onset individuals who are not, on average,
evolving faster than the average disease progression trajectory. On the other
hand, stable Alzheimer patients and MCI individuals tend to have smaller time
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shifts than stable controls. A portion of the stable MCI and most of the sta-
ble Alzheimer patients can be considered as early-onset individuals. It appears
clearly that stable Alzheimer patients and converters MCI are fast progressing
individuals even though a small number of converters MCI are slow-progressers.
On average, stable MCI and stable controls are not progressing faster than the
average disease progression scenario. These observations are coherent with the
diagnoses of the individuals and the subject- specific random effects allow to
distinguish groups of individuals which are coherent with their diagnoses. The
disease progression for Alzheimer patients and converters MCI is faster and
started earlier than for stable controls. The Alzheimer patients are quite clearly
separated from the stable controls. In the model, the random effects ηi and τi are
assumed independent, therefore uncorrelated. For this experiment, we computed
the estimated covariance matrix of the random effects. For stable controls, we
find that Corr(ηi, τi) = 0.20, for stable MCI : Corr(ηi, τi) = −0.17, for stable AD
: Corr(ηi, τi) = 0.12 and for converters MCI : Corr(ηi, τi) = 0.18. These results
seem coherent with the shape of the point clouds in the log-acceleration-time-
shift plane, especially for stable controls and stable MCI.
The cortical thickness measurements (computed with Freesurfer) were aver-
aged within 34 regions of interest defined with the Desikan-Killiany [19] cortical
atlas. The averaged cortical thickness measurements were analyzed using the
straight lines model. For each subject, time shifts and acceleration factors were
estimated and the corresponding values were displayed on the cortical surface.
The differences in the estimated time shifts and acceleration factors were com-
pared between Alzheimer patients and controls (figure 2), and between converters
MCI and stable MCI (figure 3). Significance level was set at 0.05, corrected for
multiple comparisons using Bonferroni correction. Alzheimer patients present
accelerated gray matter loss compared to stable controls in a large number of
regions, with highest speed in temporal (including entorhinal cortex, parahip-
pocampal gyrus, superior and middle temporal gyri), parietal associative (includ-
ing precuneus) and frontal regions. A similar topographical pattern was found for
converters MCI compared to stable MCI but with smaller accelerations than in
AD patients. On the contrary, primary motor and sensitive as well as visual cor-
tices were spared. These results are highly consistent with the spatial-temporal
progression patterns of neurodegeneration evidenced in histopathological studies
[16], [17]. Furthermore, accelerated atrophy has also been recently shown to co-
incide with disease-onset [18]. On the other hand, the estimated time shifts were
not significantly different for the vast majority of regions. In the few significant
regions, the magnitude of the time-shifts was small. This is in contrast with the
large time-shift values found for the cognitive variables. This can be attributed
to the slow but consistent age-related atrophy that is present in control subjects.
4 Discussion and perspectives
We proposed a statistical model which allows to model the progression of a neu-
rodegenerative disease for a group of individuals. The power of our approach
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Fig. 2. At the top (respectively bottom) : the difference in averaged acceleration factors
(respectively time shifts) between AD patients and stable controls is displayed on the
cortex. Acceleration factors (and respectively time shifts) were averaged per regions
of interest. Only regions where the difference was statistically significant (p < 0.05,
corrected for multiple comparisons) were colored.
lies in the use of subject-specific time shifts and acceleration factors which ap-
pear as random effects of our statistical model. The acceleration factor and time
shift associated to a given individual allow to define the subject-specific trajec-
tory of disease progression as an affine reparametrization of the average disease-
progression trajectory. As a consequence, the progression of a given individual
can be easily compared to the estimated average scenario and two individuals
can be compared together through the comparisons of their corresponding affine
reparametrizations. These subject-specific time shift account for delay (or ad-
vance) in disease progression. Using the logistic curves model and the straight
lines model, we showed that we were able to distinguish between fast versus slow
progressing individuals and early versus late onset individuals. However, our ex-
perimental results were based on the a priori knowledge of clinical diagnostic
informations and the statistical model we introduced does not allow to deter-
mine the sequence in which biomarkers reach pathological levels. Fonteijn et al.
proposed such an event-based model in [14]. Finally, our model was described in
a Riemannian manifold setting which ensures that the model can be applied to
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Fig. 3. At the top (respectively bottom) : the difference in averaged acceleration factors
(respectively time shifts) between converters MCI and stable MCI is displayed on the
cortex. Acceleration factors (and respectively time shifts) were averaged per regions
of interest. Only regions where the difference was statistically significant (p < 0.05,
corrected for multiple comparisons) were colored.
data of varying complexity. This also paves the way for a generalization of this
model to a multivariate framework.
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